We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2009 by Ministry of Health, Labour and Welfare, Japan.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00890279
First Posted: April 29, 2009
Last Update Posted: December 2, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Ministry of Health, Labour and Welfare, Japan
  Purpose
This phase II study examines the safety and efficacy of combination therapy for hypertension in patients with autosomal dominant polycystic kidney disease (ADPKD). This study examines the safety and efficacy of combination therapy by imidapril (ACEI) or cilnidipine (CCB) in ADPKD patients whose blood pressure is not controlled under 120/80 mmHg by candesartan (ARB) alone.

Condition Intervention Phase
Kidney, Polycystic, Autosomal Dominant Drug: Cilnidipine Drug: Imidapril Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study for the Second-Line Treatment of Hypertension in Patients With Autosomal Dominant Polycystic Kidney Disease; ACEI vs. CCB

Resource links provided by NLM:


Further study details as provided by Ministry of Health, Labour and Welfare, Japan:

Primary Outcome Measures:
  • eGFR [ Time Frame: every 6 months ]

Secondary Outcome Measures:
  • Kidney Volume measured by MRI [ Time Frame: every 3 months to every 2 years ]
  • Serum creatinine level [ Time Frame: every 3 months to every 2 years ]
  • Induction of hemodialysis, cardiovascular events and central nervous vascular events [ Time Frame: every 3 months to every 2 years ]

Estimated Enrollment: 160
Study Start Date: July 2009
Estimated Study Completion Date: November 2012
Estimated Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cilnidipine
The patients whose blood pressure is not controlled under 120/80 with ARB alone are randomized into group A or B. In group A, blood pressure is controlled by Candesartan plus Cilnidipine.
Drug: Cilnidipine
Cilnidipine up to 20 mg
Other Name: ATELEC
Active Comparator: Imidapril
The patients whose blood pressure is not controlled under 120/80 with ARB alone are randomized into group A or B. In group B, blood pressure is controlled by Candesartan plus Imidapril.
Drug: Imidapril
Imidapril up to 10 mg per day
Other Name: TANATRIL

Detailed Description:
Maximum dosage of candesartan is 8 mg/day. Dosage of imidapril is in the range of 2.5-10 mg/day. Dosage of cilnidipine is in the range of 5-20mg/day.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • ADPKD patients
  • Blood pressure measured at out-patient setting is above 120/80 mmHg
  • Age between 20 and 60 years old
  • eGFR more than 30 ml/min/1.73m2
  • Patients give informed consent

Exclusion Criteria:

  • Patients with severe cardiovascular and hepatic disorders
  • Patients with complications of central nervous vascular disorders
  • Women who are breast feeding and females of childbearing potential who are not using acceptable contraceptive methods
  • Patients currently engaging in other experimental protocol
  • Patients with intracranial aneurysma
  • Patients who must use diuretics
  • Allergic patients to Candesartan or Cilnidipine
  • Patients whose hypertension is not controlled by medication of this protocol
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00890279


Contacts
Contact: Shigeo Horie, MD +81339642497 shorie@med.teikyo-u.ac.jp
Contact: Satoru Muto, MD, PhD +81339642497 muto@med.teikyo-u.ac.jp

Locations
Japan
Department of Medicine II, Hokkaido Univserity School of Medicine Recruiting
Sapporo, Hokkaido, Japan, 0608638
Contact: Toshio Mochizuki, MD    +81117065915    mtoshi@med.hokudai.ac.jp   
Principal Investigator: Toshio Mochizuki, MD         
Toranomon Hospital Kajigaya, Kidney center Not yet recruiting
Kawasaki, Kanagawa, Japan, 2138587
Contact: Yoshihumi Ubara, MD    +81448775111 ext 6064    ubara@toranomon.gr.jp   
Principal Investigator: Yoshihumi Ubara, MD         
Department of Medicine II, Nippon Medical School Not yet recruiting
Bunkyo-ku, Tokyo, Japan, 1138602
Contact: Yasuhiko Iino, MD    +81338222131    iinoyasuhiko@nms.ac.jp   
Principal Investigator: Yasuhiko Iino, MD         
Department of Urology, Teikyo University School of Medicine Recruiting
Itabashi-ku, Tokyo, Japan, 1738605
Contact: Shigeo Horie, MD    +81339642497    shorie@med.teikyo-u.ac.jp   
Contact: Satoru Muto, MD    +81339642497    muto@med.teikyo-u.ac.jp   
Principal Investigator: Shigeo Horie, MD         
Toranomon Hospital, Kidney center Not yet recruiting
Minato-ku, Tokyo, Japan, 1058470
Contact: Kenmei Takaichi, MD    +81335881111 ext 7065    takaichi@toranomon.gr.jp   
Principal Investigator: Kenmei Takaichi, MD         
Division of Kidney and Hypertension, Department of Internal Medicine, Jikei University School of Medicine Active, not recruiting
Minato-ku, Tokyo, Japan, 1058471
Department of Urology, Kyorin University School of Medicine Not yet recruiting
Mitaka, Tokyo, Japan, 1818611
Contact: Eiji HIgashihara, MD    81422475511    ehigashi@kyorin-u.ac.jp   
Contact: Kikuo Nutahara, MD    81422475511    kinuta@kyorin-u.ac.jp   
Principal Investigator: Eiji Higashihara, MD         
Sub-Investigator: Kikuo Nutahara, MD         
Department of Urology, National Hospital Organaization Chiba-East Hospital Not yet recruiting
Chiba, Japan, 2608712
Contact: Koichi Kamura, MD    +81432615171 ext 7607    kamura@cehpnet.com   
Principal Investigator: Koichi Kamura, MD         
Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences Not yet recruiting
Niigata, Japan, 9518510
Contact: Ichiei Narita, MD    +813252272193    naritai@med.niigata-u.ac.jp   
Principal Investigator: Ichiei Narita, MD         
Sponsors and Collaborators
Ministry of Health, Labour and Welfare, Japan
Investigators
Study Chair: Shigeo Horie, MD Teikyo University
  More Information

Responsible Party: Shigeo Horie, M.D./Chairman of the Department of Urology at Teikyo University, Teikyo University, School of Medicine
ClinicalTrials.gov Identifier: NCT00890279     History of Changes
Other Study ID Numbers: ADPKDhypertension
First Submitted: April 28, 2009
First Posted: April 29, 2009
Last Update Posted: December 2, 2009
Last Verified: December 2009

Keywords provided by Ministry of Health, Labour and Welfare, Japan:
Autosomal Dominant Polycystic Kidney Disease
Hypertension
Angiotensin-II Receptor Blocker
Calcium Channel Blocker
Angiotensin converting enzyme inhibitor
Kidney Volume
eGFR

Additional relevant MeSH terms:
Hypertension
Kidney Diseases
Polycystic Kidney Diseases
Polycystic Kidney, Autosomal Dominant
Vascular Diseases
Cardiovascular Diseases
Urologic Diseases
Kidney Diseases, Cystic
Abnormalities, Multiple
Congenital Abnormalities
Genetic Diseases, Inborn
Angiotensin-Converting Enzyme Inhibitors
Imidapril
Cilnidipine
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Calcium Channel Blockers
Membrane Transport Modulators
Antihypertensive Agents